| Page 146 | Kisaco Research

Examine how AI models are being developed, validated, and governed to meet regulatory expectations, with practical insights into documentation, auditability, and lifecycle management to ensure safe, transparent, and compliant deployment in GxP environments.

Explore h ow AI models predict protein 3D structures from sequences, enabling insights into folding pathways and functional conformations
Examine emerging co-folding models that reveal protein–protein interactions and guide multimeric complex design.

Author:

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Learn how AI-driven approaches integrate multiomics data, including genomics, proteomics, and transcriptomics, to identify potential drug targets and disease biomarkers for complex diseases.
Explore how AI models synthesize cross-omic data and real-time multiomic information to uncover novel biological mechanisms, identify potential biomarkers and enable precision medicine.

Author:

Kiran Nistala

Head, Functional Genomics
Alkermes

Kiran Nistala

Head, Functional Genomics
Alkermes

Author:

David Hallett

Chief Scientific Officer
Recursion

David Hallett

Chief Scientific Officer
Recursion

Author:

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Author:

Shah Nawaz

Vice President & Chief Technology Officer
Regeneron

Shah Nawaz

Vice President & Chief Technology Officer
Regeneron

Author:

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization.

Learn how predictive simulations, generative AI and differentiating clinical biomarkers are forecasted to cut prototyping timelines by weeks and reduce per‑trial costs.

.

Author:

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck

Author:

Pavan Choksi

Partner
Arkitek Ventures

Pavan Choksi

Partner
Arkitek Ventures

Learn how  GenAI is transforming early drug discovery by designing novel, drug-like small molecules with improved potency, selectivity, and ADME properties.
Explore how GenAI integrates with synthesis planning and automation tools to prioritize viable candidates and accelerate iterative drug development.

Author:

Yue-Wang Webster

Vice President, Model Driven Drug Discovery Platforms
Eli Lilly

Yue-Wang Webster

Vice President, Model Driven Drug Discovery Platforms
Eli Lilly